Drug Trial Radar · NCT00349466
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
Last checked: Nov 20, 2026Latest source record: May 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Jan 2007
Primary completion
May 2009
Study completion May 2009
Sponsor
- Lead sponsor
- Can-Fite BioPharmaIndustry
- Sponsor type
- Industry
- First posted
- Jul 7, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe keratoconjunctivitis sicca (KCS). Patients will be randomized to receive either CF101 1 mg or matching placebo, given orally every 12 hours (q12h) for 12 weeks. A Screening Period of up to 4 weeks that includes a 2-week run-in period will precede a 12-week treatment period, followed by a 2-week follow-up period.
Conditions
- Keratoconjunctivitis Sicca
Interventions
CF101Drug
Orally CF101 1mg
PlaceboDrug
Orally matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 12 in Schirmer Test (ST) Score in MillimetersTime frame: 12 weeks
- Change From Baseline to Week 12 in Tear Break-Up Time (BUT) in SecondsTime frame: 12 weeks
- Number of Subjects With >25% Improvement in Fluorescein Staining of the Cornea (FS) at Week 12Time frame: 12 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Meir Hospital
Kfar Saba, Israel
Sheba Medical Center
Tel HaShomer, Israel
Assaf Harofeh Medical Center
Tsrifin, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.